The aim of the present work is to perform a clinical case study evaluating the concept of Dynamic-ElectroEnhanced Chemotherapy™ (D-EECT). Ten patients with squamous cell carcinoma, eight with breast cancer and five patients with each presenting a different type of tumour, were entered in the trials initiated by five different cancer centres. All the patients were given Bleomycin and 2 to 3 treatment sessions with IQWave™ (Scandinavian ChemoTech AB, Sweden) according to the D-EECT protocol, which starts with pulses of amplitude 1000 V that successively reduces to about 400 V with an electrode distance of 12 mm. An average complete response of 26% and an average partial response of 74% add up to 100% objective response for all treated tumours. A new quantity “weighted response” WR = (3 х CR + PR - 3 х PD)/3 was introduced, that considers the cases of progressive disease (PD) as well. For the 10 cases of squamous cell carcinoma in the present study the weighted response was 47%. Considering squamous cell carcinoma (SCC) tumours larger than 3 cm the weighted response of 47% in the present study is about twice the WR of 23% for SCC tumours > 3 cm treated according to the European Standard operating procedures (ESOPE) protocol. The WR results of breast cancer, 43-67%, in the present study are almost equal to the WR averages of 47-80% in treatment of breast cancer nodules of different sizes according to the ESOPE protocol. The WR result of 67% for patients with breast-infiltrated ductal carcinoma with large, 10-15 cm, tumours is however, better than the WR of 47% for tumours larger than 3 cm in breast cancer patients treated according to the ESOPE protocol. In clinical studies of various types of tumours treated according to the ESOPE protocol an average of about 5% progressive disease was recorded, whereas no cases of progressive disease was recorded in the present study.
View Full Article